Coronado Biosciences, Inc. announced the appointment of Kevin Horgan as its Chief Medical Officer. Dr. Horgan will oversee the company's clinical development programs and regulatory and medical affairs activities for its lead product candidates, TSO (Trichuris suis ova or CNDO-201) and CNDO-109. Prior to joining Coronado, he was Senior Vice President and Chief Medical Officer at Soligenix, Inc. since 2011.